To evaluate the antitumoral efficacy of everolimus in pituitary carcinoma resistant to
temozolomide, the correlation with mammalian target of rapamycin (mTOR) signaling in the …

Objectives Only few retrospective studies have reported an efficacy rate of temozolomide
(TMZ) in pituitary tumors (PT), all around 50%. However, the long-term survival of treated …

Context: To date only 18 patients with aggressive pituitary tumors or carcinomas treated with
temozolomide have been reported. Increased expression of O 6-methylguanine-DNA …

Temozolomide (TMZ) has been shown as an effective treatment option in aggressive
pituitary adenomas and carcinomas. This review analyses the published case series and …

Eur J Clin Invest 2011; 41 (10): 1133–1148 Abstract Background Aggressive pituitary
tumours are associated with substantial morbidity and mortality. Treatment options are often …

Temozolomide is an alkylating chemotherapeutic agent used in malignant neuroendocrine
neoplasia, melanoma, brain metastases and an essential component of adjuvant therapy in …

Temozolomide is an oral chemotherapy used to treat aggressive pituitary tumours since
2006. It is inexpensive and well tolerated, the main side effects are fatigue, nausea and …

Introduction Temozolomide (TMZ) is an oral alkylating agent that has been used over the
past 8 years to treat aggressive pituitary tumors resistant to conventional therapy. To date …

Context Despite growing evidence that temozolomide (TMZ) therapy is effective for the
treatment of aggressive pituitary tumors (APTs) or carcinomas (PCs), individual therapy …

The use of temozolomide (TMZ) for the management of aggressive pituitary tumours (APT)
has revolutionised clinical practice in this field with significantly improved clinical outcomes …